Showing results (341-350 of 441) with videos related to
Sort By:
Pageof 45
International Journal of Radiation Oncology, Biology, Physics|May 7, 2023
Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001Vinai Gondi, Snehal Deshmukh, Paul D Brown, et al.Neuro-Oncology|February 21, 2018
Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group databaseDeborah T Blumenthal, Minhee Won, Minesh P Mehta, et al.Cell|April 15, 2021
Synthetic lethality-mediated precision oncology via the tumor transcriptomeJoo Sang Lee, Nishanth Ulhas Nair, Gal Dinstag, et al.Cancer|October 26, 2018
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastomaStefania Maraka, Morris D Groves, Aaron G Mammoser, et al.Neuro-Oncology|August 5, 2011
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?Jennifer L Clarke, Michele M Ennis, W K Alfred Yung, et al.Journal of Neuro-Oncology|June 30, 2009
Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomaAndrew D Norden, Jeffrey J Raizer, Lauren E Abrey, et al.Acta Neuropathologica|February 1, 2022
High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13Drew Pratt, Zied Abdullaev, Antonios Papanicolau-Sengos, et al.Neuro-Oncology|February 12, 2011
Clinical trial end points for high-grade glioma: the evolving landscapeDavid A Reardon, Evanthia Galanis, John F DeGroot, et al.Oncotarget|May 10, 2015
Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapyHui Xu, Shervin Rahimpour, Cody L Nesvick, et al.Neuro-Oncology|February 13, 2010
A multigene predictor of outcome in glioblastomaHoward Colman, Li Zhang, Erik P Sulman, et al.Pageof 45